Digital Health Market Segmentation
A useful map. Not 14 buzzwords.
Six durable segments inside digital health, with the buyer, business model and competitive moat that actually defines each — for investors and pharma digital teams.
"Which digital-health segment is worth backing, and why?"
The "digital health" label collapses six very different markets. Telehealth and RPM are payer-driven; AI diagnostics is provider-driven; data platforms are pharma-driven. Treating them as one market is the most expensive mistake investors keep making.
“Digital health” is a label, not a market. Treating it as one is why so many digital-health funds underperformed: the underlying buyer economics are radically different.
Six segments. Six business models.
Telehealth, RPM, AI diagnostics, health-data platforms, behavioral / mental-health, and pharma-services digital. Each has a distinct buyer, sales motion, gross margin profile and defensibility pattern.
Use the buyer, not the technology, as the segmentation axis
The fastest way to make the segmentation defensible is to start from who pays. Once you do, AI imaging and behavioral health stop competing for the same wallet — and your conviction list compresses fast.
What we’re seeing in the data.
The buyer defines the segment
Provider, payer, pharma, employer and consumer are different markets with different gross margins and CAC.
Telehealth flat-lines without RPM
Pure synchronous telehealth has plateaued; RPM, hybrid care and chronic-disease management are where unit economics work.
AI diagnostics depends on workflow integration
Standalone AI products struggle; embedded AI inside imaging/EHR workflow wins reimbursement and adoption.
Pharma-services digital is the quietest big market
Trial recruitment, patient support and HCP engagement platforms compound on long enterprise contracts.
How to think about it.
-
01
Anchor segmentation by buyer
Provider / payer / pharma / employer / consumer — economics differ by 10× across these.
-
02
Score reimbursement reality
CPT codes, MIPS incentives and PMPM rates define which models scale.
-
03
Map workflow integration
EHR, imaging or claims integration depth predicts adoption velocity.
-
04
Test data network effects
Defensibility lives in proprietary data accumulation, not features.
-
05
Stress-test enterprise sales motion
Long sales cycles, security reviews, and clinical evidence are real costs.
What separates a good answer from a defensible one.
HIPAA, HITRUST and EU MDR add 6–12 months to enterprise launches.
Peer-reviewed outcomes data accelerates payer and provider adoption far more than ROI calculators.
Point solutions get squeezed by platform players bundling functionality.
US payer model differs sharply from EU/APAC public-system economics.
Where the signal comes from.
Common questions.
Is "digital health" really one market?
No — it’s six. Lumping them together hides the unit economics and competitive dynamics that actually drive returns.
Which segment has the best unit economics?
Pharma-services and embedded clinical AI tend to have stronger gross margin and retention than consumer-facing digital health.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist